Clinical Trials Directory

We are doing this to compare the results of early surgical intervention to medical therapy. We want to know if there is a difference in outcomes for these treatment options. We also want to track the health and progress of people with a large ascending aortic aneurysm (a bulge in the aorta caused by weakening in the artery wall).

We are doing this study to find out if 2 investigational drugs called aliocumab and cemiplimab (the study drugs) are a safe and effective option to treat NSCLC that has spread to other organs in the body and help patients live disease free for a longer period of time.

We are doing this research study to learn about the safety and effectiveness of alirocumab (a cholesterol-lowering drug) when it is combined with cemiplimab (an immunotherapy drug) and preoperative chemotherapy in patients with stage 1B-3A non-small cell lung cancer (NSCLC) who will undergo surgery. This study is important because it might potentially improve outcomes for you and other future patients.

We are doing this to study to test how well an investigational technology called the Endospan NEXUS Aortic Arch Stent Graft System (the study device) performs in the treatment of aortic arch disease.

We are doing this study to find the most effective, safe dose of an experimental drug called rilvegostomig (the study drug). We want to know how well the study drug works on its own and when it is used in combination with another anti-cancer drug called datopotamab deruxtecan (also called Dato-DXd). We will compare how well both of these regimens work versus the standard treatment for non-small cell lung cancer (NSCLC) that is ctDNA-positive.

We are doing this study to find the safest and most effective dose of an experimental drug called Dato-DXd (the study drug) in patients with triple negative breast cancer (TNBC) and HER2-negative breast cancer.

We are doing this study to help women regain bladder strength and function after having their first baby. We want to find out which treatment options work best to stop bladder leakage.

We are doing this study to find out if an investigational drug called TYRA-300 (the study drug) is a safe and effective option for patients with locally advanced/metastatic urothelial cancer and other solid tumors.